Publication: Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice
Issued Date
2018-09-01
Resource Type
ISSN
10969071
01466615
01466615
Other identifier(s)
2-s2.0-85049779290
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Medical Virology. Vol.90, No.9 (2018), 1431-1437
Suggested Citation
Frank van Someren Gréve, Koenraad F. van der Sluijs, Anita M. Tuip, Marcus J. Schultz, Menno D. de Jong, Nicole P. Juffermans Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice. Journal of Medical Virology. Vol.90, No.9 (2018), 1431-1437. doi:10.1002/jmv.25212 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45972
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice
Other Contributor(s)
Abstract
© 2018 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc. Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection. Influenza A (H3N2) virus–infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control 2 days postinfection. Seven days later, both groups were infected with Streptococcus pneumoniae and killed 18 hours later. Mice receiving AT10_002 showed less loss of bodyweight compared with controls (+1% vs −12%, P <.001), lower viral loads in bronchoalveolar lavage fluids (BALFs) (7 vs 194 RNA copies per µL; P <.001), and reduced bacterial outgrowth in lung homogenates (3.3 × 10 1 vs 2.5 × 10 5 colony-forming units per mg; P <.001). The treatment group showed lower pulmonary wet weights, lower cell counts, and lower protein levels in BALF compared with controls. Treatment with AT10_002 was associated with lower levels of tumor necrosis factor-α, interleukin (IL)-6, cytokine-induced neutrophil chemoattractant (KC), and interferon-γ in BALF and lower IL-6 and KC in lung homogenates. Treatment with anti-influenza antibody AT10_002 is associated with reduced weight loss, viral load, bacterial outgrowth, and lung injury in a murine model of secondary pneumococcal pneumonia following influenza infection.